Physician profile
Adnan Khan
NPI 1285928705
$30,874.39
in general payments reported to CMS, 2019-2025
53 companies · $4,041 in 2025
The $4,041 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,900 · 2020: $1,128 · 2021: $1,574 · 2022: $5,308 · 2023: $9,355 · 2024: $3,568 · 2025: $4,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,437 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,600 · Travel and Lodging: $1,875 · Education: $52.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,436.92 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,600.00 |
| Travel and Lodging | $1,874.85 |
| Education | $52.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $7,301.69 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic Vascular, INC. | $4,432.06 | 2019-2020 | |
| Abbott Laboratories | $4,209.92 | 2019-2025 | Aveir, Navitor, Cardiomems |
| Medtronic, INC. | $3,144.14 | 2019-2025 | Micra, Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| Edwards Lifesciences Corporation | $1,274.28 | 2022-2025 | Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,054.74 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $979.40 | 2019-2024 | Xarelto |
| Amgen INC. | $867.89 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $811.18 | 2019-2025 | |
| Novo Nordisk INC | $675.51 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $561.22 | 2022-2025 | Verquvo |
| Abiomed | $550.40 | 2019-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $511.55 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $433.83 | 2019-2025 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $362.31 | 2022-2024 | Optimizer, Optimizer |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adnan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.